IL6 and acute myeloid leukemia: The leukaemic BM is a pro‐inflammatory, cytokine‐rich environment,11 and many of these factors, such as IL6, play important roles in AML biology.12, 13 Cytokines and inflammation, especially related to cancer, have been shown to suppress hepatic and intestinal CYP levels.16, 17 For the initial treatment of newly diagnosed AML patients, the ‘7 + 3’ regimen, which combines a 7‐day continuous intravenous infusion of cytarabine with a short infusion of an anthracycline given on days 1‐3, remains the most commonly used regimen.